Mylan NV (MYL.O)
2 Dec 2016
* Mylan NV says on November 22, 2016, entered into a revolving credit agreement
WASHINGTON The U.S. Senate Judiciary Committee on Monday postponed a hearing planned for next week to discuss Mylan NV's pending $465 million settlement to resolve charges that it underpaid government healthcare programs by misclassifying its EpiPen emergency allergy treatment.
Mylan NV has declined a U.S. Senate committee request to testify about a $465 million pending settlement to resolve charges the company underpaid government healthcare programs by misclassifying its the EpiPen emergency allergy treatment.
Nov 21 Mylan NV has declined a U.S. Senate committee request to testify about a $465 million pending settlement to resolve charges the company underpaid government healthcare programs by misclassifying its the EpiPen emergency allergy treatment.
* Says Mylan declining to testify at judiciary committee hearing on potential settlement between Mylan and DOJ Source text - (http://bit.ly/2fy1MoP) Further company coverage:
LONDON, Nov 21 (IFR) - Corporate borrowers on both sides of the Atlantic shrugged off concerns about global volatility last week with pharmaceutical companies leading the charge, although they had to pay significantly higher premiums.
* Ups share stake in Mylan NV by 29.4 percent to 6.4 million shares - SEC filing
LONDON, Nov 14 (IFR) - US pharmaceuticals AbbVie and Mylan have set their sights on Europe's bond market to sell debut euro bonds, taking advantage of positive sentiment for the sector after last week's unexpected Donald Trump victory in the US election.
Perrigo Co Plc reported a higher-than-expected adjusted quarterly profit and said it would review strategic options for royalty rights from sales of multiple sclerosis drug Tysabri.
* Shares up 4 pct in premarket trading (Adds details, shares)